Medical

Glenmark Pharmaceuticals recently said that a Phase 3 study comparing Ryaltris olopatadine hydrochloride to placebo in seasonal allergic rhinitis patients aged 6 up to 12 years achieved its primary endpoint. The 14-day study, which enrolled… Read more . . .

Verona Pharma said that it has initiated a Phase 2b dose-ranging study of RPL554 nebulized ensifentrine for the treatment of COPD, with results expected by the end of 2019. The company, which reported positive results… Read more . . .

GlaxoSmithKline and Innoviva have announced that the Phase 3 CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study comparing the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI to the Relvar/Breo Ellipta… Read more . . .

Marinomed Biotech has announced that a Phase 3 trial of Budesolv budesonide nasal spray has met its primary endpoint. Without providing any specific data, the company said that, “The top line results are now available… Read more . . .

Novus Therapeutics said that two Phase 1 trials of its OP0201 intranasal MDI, which is in development for otitis media, both met their primary endpoints. In one of the studies, healthy adults received either a… Read more . . .

The UK’s National Institute for Health Care and Excellence (NICE) has issued a new “patient decision aid” that emphasizes that a metered dose inhaler “contains propellant, so it has a higher carbon footprint than a… Read more . . .

VistaGen Therapeutics has presented new data from a Phase 3 study of PH94B nasal spray for the treatment of social anxiety disorder (SAD) at the 2019 Anxiety and Depression Association of America (ADAA) Annual Conference.… Read more . . .

Savara has announced the initiation of the Phase 2a ENCORE study of its Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection in cystic fibrosis patients. The… Read more . . .